Supernus Pharms Company Profile
✉ Email this page to a colleague
What is the competitive landscape for SUPERNUS PHARMS, and what generic alternatives to SUPERNUS PHARMS drugs are available?
SUPERNUS PHARMS has five approved drugs.
There are fifty-six US patents protecting SUPERNUS PHARMS drugs. There is one tentative approval on SUPERNUS PHARMS drugs.
There are ninety-two patent family members on SUPERNUS PHARMS drugs in thirteen countries and two supplementary protection certificates in two countries.
Summary for Supernus Pharms
| International Patents: | 92 |
| US Patents: | 56 |
| Tradenames: | 5 |
| Ingredients: | 4 |
| NDAs: | 5 |
Drugs and US Patents for Supernus Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Supernus Pharms | GOCOVRI | amantadine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 208944-001 | Aug 24, 2017 | AB | RX | Yes | No | 11,065,213 | ⤷ Sign Up | Y | ⤷ Sign Up | ||
| Supernus Pharms | OXTELLAR XR | oxcarbazepine | TABLET, EXTENDED RELEASE;ORAL | 202810-002 | Oct 19, 2012 | AB | RX | Yes | No | 8,617,600 | ⤷ Sign Up | Y | ⤷ Sign Up | ||
| Supernus Pharms | OSMOLEX ER | amantadine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 209410-003 | Feb 16, 2018 | DISCN | Yes | No | 10,213,393 | ⤷ Sign Up | ⤷ Sign Up | ||||
| Supernus Pharms | QELBREE | viloxazine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 211964-002 | Apr 2, 2021 | RX | Yes | No | 11,324,753 | ⤷ Sign Up | ⤷ Sign Up | ||||
| Supernus Pharms | TROKENDI XR | topiramate | CAPSULE, EXTENDED RELEASE;ORAL | 201635-004 | Aug 16, 2013 | AB1 | RX | Yes | Yes | 9,622,983 | ⤷ Sign Up | Y | ⤷ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Supernus Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Supernus Pharms | OSMOLEX ER | amantadine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 209410-001 | Feb 16, 2018 | RE39069 | ⤷ Sign Up |
| Supernus Pharms | OSMOLEX ER | amantadine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 209410-002 | Feb 16, 2018 | RE39069 | ⤷ Sign Up |
| Supernus Pharms | OSMOLEX ER | amantadine hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 209410-003 | Feb 16, 2018 | RE39069 | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for SUPERNUS PHARMS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Extended-release Capsules | 200 mg | ➤ Subscribe | 2014-04-03 |
| ➤ Subscribe | Extended-release Tablets | 150 mg and 300 mg | ➤ Subscribe | 2013-04-12 |
| ➤ Subscribe | Extended-release Capsules | 25 mg, 50 mg, and 100 mg | ➤ Subscribe | 2014-05-12 |
International Patents for Supernus Pharms Drugs
Supplementary Protection Certificates for Supernus Pharms Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2317997 | 2190050-1 | Sweden | ⤷ Sign Up | PRODUCT NAME: PHENTERMINE AND TOPIRAMATE; NAT. REG. NO/DATE: 59574-59577 20210617; FIRST REG.: IS IS/1/21/018/01-04 20210212 |
| 0138441 | SPC/GB95/028 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: TOPIRAMATE; REGISTERED: UK 0242/0301 19950718 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
